Being born with a life limiting disease that demands a burdensome regime of drugs and treatments every single day is hard enough but add to this limited access to treatments that improve health and quality of life. This is just unfair!

The plight of many people with cystic fibrosis (CF) is being further complicated by unnecessary restrictions on the combined use of certain drug treatments such as Bronchitol and Pulmozyme - even though these drugs are each funded by the PBS.

Pharmaxis, the maker of Bronchitol has lodged a Pharmaceutical Benefits Advisory Committee (PBAC) submission asking that eligible people with CF have access to both PBS funded Bronchitol and the PBS funded Roche drug Pulmozyme together.

Existing prescribing restrictions make it difficult for people with CF to use Bronchitol alongside their nebulised Pulmozyme and currently, the only way to access this is via a compassionate use program which can make prescribing complicated for clinics and patients and may mean that many people are not offered this treatment option.

While this specific combination is not a universal remedy, some people with CF will get significant benefit from taking both the inhaled mannitol, Bronchitol and nebulised Pulmozyme in combination.

Cystic Fibrosis Australia believes it is important that people with CF are offered a variety of treatments tailored to the unique aspects of their disease and situation. If you also believe unlimited access to the best treatments is paramount then register your support at http://www.health.gov.au/internet/main/publishing.nsf/Content/PBAC_online_submission_form

CFA strongly advocates for better health outcomes and quality of life, helping empower people with CF to lead productive lives and all the salient points about Bronchitol can be found on Cystic Fibrosis Australia’s website www.cfa.org.au .

Bronchitol is safe, significantly improves mucus clearance and lung function and reduces exacerbations. Wherever possible if the effects of this drug can be enhanced through combination treatments, this is something not simply worth fighting for, it’s critically important.

Access to the most suitable medications is key to ensure effective personalise health regimes are possible and if you would like to do your bit have your say on the PBAC portal.

If you would like to tell your story to the media or our politicians in Canberra contact Vanessa at CFA by email vanessak@cfa.org.au

Regards

Nettie Burke
CEO
Cystic Fibrosis Australia